3Hartmann RW, Ehmer PB, Haidar S, et al. Inhibition of CYP 17, a new strategy for the treatment of prostate cancer. Arch Pharm ( Weinheim), 2002,335 (4): 119.
4Madigan MP, Gao YT, Deng J,et al. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population - based study in China. Int J Cancer, 2003 ,107(2) :271.
5Yamada Y, Watanabe M, Murata M, et , al. Impact of genetic polymorphisms of 17 - hydroxylase cytochrome P -450 (CYP17)and steroid 5alpha - reductase type Ⅱ (SRD5A2) genes on prostate - cancer risk among the Japanese population. Int J Cancer,2001 ,92(5) :683.
8Ho SM. Estrogens and anti -estrogens: key mediators of prostate carcinogenesis and newtherapeutic candidates. J Cell Biochem,2004 ,91(3) :491.
9Chen TC, Holick MF. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab,2003 , 14 (9) :423.
10Stewart LV, Weigel NL. Vitamin D and prostate cancer. Exp Biol Med (Maywood) ,2004 ,229(4) :277.
二级参考文献14
1[1]Fukuoka H,Ishibashi Y,Sakai N,et al. The evaluation of the effect of Estracyt on prostatic cancer. Hinyokika kiyo 1991;Jan;37(1):91～97
2[2]Morote J,Lopez-Pacios MA,Ahmad A,et al. Treatment of hormone-refractory prostate cancer with estramustine phosphate.Actas Urol Esp 1991 Sel-Oct;15(5):421
3[3]Van Poppel H,Baert L. The present role of estramustine phosphate in advanced prostate cancer. Prog Clin Biol Res 1991;370:323～341
4[4]Hudes G. Estramustine-based chemotherapy. Semi Urol Oncol 1997 Feb;15(1) :13～19
5Bono AV. Leuprorelin-continuing advances in the treatment of prostate cancer. Bionledis,1997,2:4.
6okada H, Doken Y,Ogawa Y, et al, Sustaied suppresion of the pituitary gonadal axis by leuororelin three-month depot microspheeres in rats and dogs, Pharmaceutical Research, 1994,11:1199.
7Labrie F,Belanger A,Dupont A.et al.,Science behind total androgen btockade: from gene to combination therapy. Clin Invest Med,1993,16:475.
8Labrie F. At the cutting edge intracrinology.Molecular Cellular Endocrinology, 1991, 78:C113.
9Parmar H, Edwards L, Phillips RH, et al, Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol, 1987,59:248.
10Neumann F,Kalmus J. Physiological principles of androgen regulation in the hormonal treatment of sexual deviations. Berlio: Diesbach,1991.8-11.
3LASSI K,DAWSON N A. Update on castrate-resistant prostate cancer: 2010 [ J ]. Curr Opin Oncol, 2010,22 ( 3 ) : 263 -267.
4HEIDENREICH A,BOLLA M,JONIAU S,et al. Guidelines on prostate cancer [ C ]. Baycelona : edition presented at the 25th EAu Annual congress ,2010:83-161.
5OH W K. The evolving role of estrogen therapy in prostatecancer [ J ]. Clin Prostate Cancer, 2002,1 ( 2 ) : 81-89.
6LIMONTA P, MONTAGNAN1 M M, MORETTI R M. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action [ J ]. Expert Opin Investig Drugs, 2001,10 (4) :709-720.
7TOLLS G, ACKMAN D, STELLOS A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists [ J ]. Proc Natl Acad Sci USA, 1982,79 ( 5 ) : 1658-1662.
8NOVARA G,GALFANO A, SECCO S, et al. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients [ J ]. Urol Int, 2009,82 ( 3 ) : 249 - 255.
9KIRBY R S, FITZPATRICK J M, CLARKE N. Abarelix and other gonadotrophinreleasing hormone antagonists in prostate cancer[ J ]. BJU Int ,2009,104 ( 11 ) : 1580-1584.
10TRACHTENBERG J, GITFLEMAN M, STEIDLE C,et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer [ J ]. J Urol, 2002, 167 ( 4 ) : 1670 - 1674.
